RNLX Key Statistics, Chart & Performance
The current stock price of RNLX is 0.2071 USD. In the past month the price decreased by -26.3%. In the past year, price decreased by -82.15%.
RNLX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| VEEV | VEEVA SYSTEMS INC-CLASS A | 28.36 | 36.08B | ||
| DOCS | DOXIMITY INC-CLASS A | 26.4 | 8.15B | ||
| WAY | WAYSTAR HOLDING CORP | 23.41 | 6.00B | ||
| HTFL | HEARTFLOW INC | N/A | 2.47B | ||
| CERT | CERTARA INC | 17.48 | 1.39B | ||
| SDGR | SCHRODINGER INC | N/A | 1.32B | ||
| TDOC | TELADOC HEALTH INC | N/A | 1.25B | ||
| CCLDO | CARECLOUD INC - CCLD 8 3/4 PERP | 650 | 1.10B | ||
| LFMDP | LIFEMD INC - LFMD 8 7/8 PERP | N/A | 1.12B | ||
| PHR | PHREESIA INC | N/A | 976.53M | ||
| GDRX | GOODRX HOLDINGS INC-CLASS A | 7.86 | 933.43M | ||
| CTEV | CLARITEV CORP | N/A | 560.20M |
Related stock screener links
About RNLX
Company Profile
Renalytix Plc engages in the manufacturing of medical devices and equipment. The firm is engaged in a field of bioprognosis for kidney health. The firm has engineered a solution that enables early-stage chronic kidney disease progression risk assessment. The Company’s lead product, KidneyIntelX platform, is designed to scale across kidney disease conditions beyond diabetic kidney disease. The company is evaluating a range of indications in chronic kidney disease, cardio-renal disease, chronic kidney disease in diverse populations and COVID-related kidney disease. KidneyIntelX has been granted designation by the United States Food and Drug Administration and is designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery.
Company Info
RENALYTIX AI PLC-ADR
Finsgate, 5-7 Cranwood Street
London SOUTH GLAMORGAN CF64 2EZ GB
CEO: James McCullough
Employees: 102
Phone: 442920710570
RENALYTIX AI PLC-ADR / RNLX FAQ
What does RNLX do?
Renalytix Plc engages in the manufacturing of medical devices and equipment. The firm is engaged in a field of bioprognosis for kidney health. The firm has engineered a solution that enables early-stage chronic kidney disease progression risk assessment. The Company’s lead product, KidneyIntelX platform, is designed to scale across kidney disease conditions beyond diabetic kidney disease. The company is evaluating a range of indications in chronic kidney disease, cardio-renal disease, chronic kidney disease in diverse populations and COVID-related kidney disease. KidneyIntelX has been granted designation by the United States Food and Drug Administration and is designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery.
What is the current price of RNLX stock?
The current stock price of RNLX is 0.2071 USD. The price increased by 5.66% in the last trading session.
Does RNLX stock pay dividends?
RNLX does not pay a dividend.
What is the ChartMill technical and fundamental rating of RNLX stock?
RNLX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the PE ratio for RNLX stock?
RENALYTIX AI PLC-ADR (RNLX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.61).
What is the expected growth for RNLX stock?
The Revenue of RENALYTIX AI PLC-ADR (RNLX) is expected to grow by 39.85% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the ownership structure of RENALYTIX AI PLC-ADR (RNLX)?
You can find the ownership structure of RENALYTIX AI PLC-ADR (RNLX) on the Ownership tab.
RNLX Technical Analysis
RNLX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to RNLX. RNLX has a bad profitability rating. Also its financial health evaluation is rather negative.
RNLX Financial Highlights
Over the last trailing twelve months RNLX reported a non-GAAP Earnings per Share(EPS) of -0.61. The EPS increased by 27.23% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -109.75% | ||
| ROE | -250.48% | ||
| Debt/Equity | 0.41 |
RNLX Forecast & Estimates
5 analysts have analysed RNLX and the average price target is 2.67 USD. This implies a price increase of 1187.44% is expected in the next year compared to the current price of 0.2071.
For the next year, analysts expect an EPS growth of 59.3% and a revenue growth 39.85% for RNLX